Published online before print July 21, 2005, doi: 10.1161/01.ATV.0000178991.71605.18
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Brief Reviews |
Atherosclerotic Plaque Progression and Vulnerability to Rupture
Angiogenesis as a Source of Intraplaque Hemorrhage
From the CVPath, International Registry of Pathology (R.V., F.D.K.), Gaithersburg, Md; Department of Pathology (A.P.B.), University of Maryland, Baltimore; Cardiac Unit (H.K.G., A.V.F.), Department of Internal Medicine, Massachusetts General Hospital, Boston; Department of Surgery (T.N.T.), Thomas Jefferson University, Philadelphia, Pa; Department of Chemical Engineering (S.P.W.), Drexel University, Philadelphia, Pa; and Department of Cardiology (J.N.), University of California, Irvine.
Correspondence to Renu Virmani, MD, Medical Director, CVPath, International Registry of Pathology, 19 Firstfield Rd, Gaithersburg, MD 20878. E-mail rvirmani{at}cvpath.org
 |
Abstract |
|---|
Top
Abstract
IntroductionObservational studies of necrotic core progression identify intraplaque hemorrhage as a critical factor in atherosclerotic plaque growth and destabilization. The rapid accumulation of erythrocyte membranes causes an abrupt change in plaque substrate characterized by increased free cholesterol within the lipid core and excessive macrophage infiltration. Neoangiogenesis is associated closely with plaque progression, and microvascular incompetence is a likely source of intraplaque hemorrhage. Intimal neovascularization is predominantly thought to arise from the adventitia, where there are a plethora of pre-existing vasa vasorum. In lesions that have early necrotic cores, the majority of vessels invading from the adventitia occur at specific sites of medial wall disruption. A breech in the medial wall likely facilitates the rapid in-growth of microvessels from the adventitia, and exposure to an atherosclerotic environment stimulates abnormal vascular development characterized by disorganized branching and immature endothelial tubes with "leaky" imperfect linings. This network of immature blood vessels is a viable source of intraplaque hemorrhage providing erythrocyte-derived phospholipids and free cholesterol. The rapid change in plaque substrate caused by the excessive accumulation of erythrocytes may promote the transition from a stable to an unstable lesion. This review discusses the potential role of intraplaque vasa vasorum in lesion instability as it relates to plaque rupture.
Intraplaque hemorrhage is a major contributor to coronary lesion progression. The formation of immature blood vessels within a plaque promotes red blood cell leakage, an important source of free cholesterol. This review discusses the potential role of angiogenesis in lesion instability as it relates to plaque rupture.
Key Words: angiogenesis • plaque rupture • sudden coronary death • free cholesterol • hemorrhage
|
Introduction |
|---|
The causes of coronary lesion progression from an asymptomatic fibroatheromatous plaque to a lesion at high risk for rupture (thin cap fibroatheroma or "vulnerable plaque") are not fully understood. Recently, our laboratory showed that intraplaque hemorrhage is an important process in the progression of asymptomatic plaques into high-risk unstable lesions.1 Red blood cell (RBC) membranes are rich in phospholipids and free cholesterol, and their accumulation within plaques plays a key role in promoting lesion instability through necrotic core expansion and inflammatory cell infiltration. The source of RBCs within coronary lesions is likely provided by inherently leaky immature blood vessels that surround and invade the plaque. Understanding the mechanisms by which plaque angiogenesis and hemorrhage occurs may ultimately help prevent the transition from a stable to an unstable lesion.
|
Plaque Rupture Is the Dominant Cause of Acute Coronary Thrombosis |
|---|
Plaque rupture is the principal cause of luminal thrombosis in acute coronary syndromes occurring in 75% of patients dying of an acute myocardial infarction.2 The plaques that are vulnerable to rupture are characterized by the same histopathologic signatures, except that they still have an intact fibrous cap, albeit thin.3–5 The fibrous cap is focally interrupted in plaque ruptures, allowing circulating blood to come in direct contact with the thrombogenic contents of the lipid-rich core, leading to thrombosis and acute coronary syndromes. Ruptured plaques possess a large necrotic core with an overlying thin-ruptured fibrous cap heavily infiltrated by foamy macrophages (Table 1; also see the online supplement, available at http://atvb.ahajournals.org). In ruptured lesions, the necrotic core occupies approximately one third to one half of the total plaque area, whereas in the majority of unruptured vulnerable plaques, it occupies less than one fourth of the lesion (Table 1).6 This observation suggests that the progressive necrotic core expansion precedes plaque rupture.
|
|
Plaque Progression as Evidenced by Morphology |
|---|
Pathologic intimal thickening (PIT) constitutes the earliest atherosclerotic change and is characterized by surface smooth muscle cells (SMCs) overlying relatively acellular lipid-rich pools. The pools of accumulated lipid likely occur from the loss of SMCs.7,8 The proteoglycan matrix within the lipid pool remains intact with a paucity of free cholesterol and the beginnings of focal-speckled calcification. When macrophages infiltrate the lipid pool, the entrapment and death of these cells is thought to be responsible for the conversion of PIT into early fibroatheroma. The combination of greater macrophage infiltration and apoptotic death together with hypoxia-induced necrosis promotes development into the late fibroatheromatous lesion. As the plaque enlarges, the ensuing hypoxia or inflammatory cell infiltration is thought to promote neovascularization (Figure 1). These nascent immature blood vessels are inherently leaky and permit extravasation of erythrocytes into the plaque, further contributing to necrotic core enlargement (Figure 2).
|
|
|
Necrotic Core Enlargement Is Critical for Plaque Rupture |
|---|
It has been shown that macrophage infiltration is the first step toward the eventual formation of an atherosclerotic plaque.9 In vitro studies have shown that low-density lipoprotein (LDL) uptake by macrophages is facilitated by a 2-step oxidation process, beginning with mild oxidation of lipid10,11 followed by apolipoprotein B oxidation, a modification required for scavenger receptor recognition, which is unaffected by the cholesterol content of the cell.12 Cultured macrophages exposed to oxidized LDL are richer in free cholesterol than cholesterol esters. The threshold level of free cholesterol in macrophages is in part regulated by a re-esterification process involving acyl coenzyme A:acylcholesterol transferase, or ACAT1.13 Manipulating the activity or expression of ACAT1 in culture14,15 or animal models16 favors the accumulation of free cholesterol. The formation of necrotic core is attributed mostly to the death of macrophages.13,17 As plaques progress from fatty streaks to those with necrotic cores (gruel plaques), the free cholesterol content of the lesion increases, whereas cholesterol esters decrease.18 The increase in free cholesterol may be closely associated with lesion instability. In a study by Felton et al of human aortic atherosclerotic plaques, the progression from nondisrupted to disrupted lesions is accompanied by increased free cholesterol, cholesterol esters, and free-to-esterified cholesterol ratio in the necrotic core; the triglyceride content is unchanged.19 The influence of lipid composition on plaque instability in coronary sudden death is also apparent from our own studies, in which the percentage of cholesterol clefts are greater in lesions with rupture compared with eroded or stable plaques (Table 1).4
It is generally accepted that apoptotic macrophages are a likely source of free cholesterol in plaques; however, it is entirely feasible that free cholesterol within the necrotic core could be derived from other sources, including erythrocyte membranes.13 In a recent investigation of thromboembolic pulmonary hypertension, Arbustini et al showed that necrotic cores in intimal plaques in large pulmonary arteries contain RBCs (as demonstrated by anti-glycophorin A staining) and macrophages. In addition, we21,22 and others20 have observed extravasated erythrocytes in disease processes outside the coronary circulation are accompanied by deposits of free cholesterol and foamy macrophages. It is well appreciated that the cholesterol content of erythrocyte membranes exceeds that of all other cells in the body, with lipid constituting 40% of the weight.23,24 Moreover, erythrocyte membrane-derived cholesterol is elevated in patients with hypercholesterolemia and is sensitive to short-term statin therapy.25,26 Because RBCs are not capable of synthesizing lipids "de novo," most of the membrane lipid content originates from an exchange with plasma lipoproteins. The level of sphingomylenase activity in plaques should be sufficient to catalyze the release of cholesterol from RBC membranes.27,28 In addition, excess membrane cholesterol can phase separate and form metastable membrane domains consisting of pure cholesterol arranged in a tail-to-tail orientation, creating a nidus for nucleation to crystalline cholesterol.29
In the early to mid-20th century, several leading pathologists forwarded the hypothesis that intraplaque hemorrhage is a major contributor to the progression of coronary atherosclerosis; however, the precise nature of this relationship was not well understood.30–32 Recent studies from our laboratory suggest that plaque hemorrhages are more frequent in the coronary vasculature in patients dying from rupture compared with plaque erosion or stable lesions with a >75% cross-section area of luminal narrowing (Figure 2).6 In an effort to further understand the influence of intraplaque hemorrhage on lesion progression, we examined various types of human coronary plaques for hemorrhagic events.1
In a relatively large series of human coronary plaques from sudden coronary death victim, there was a greater frequency of previous hemorrhages in coronary atherosclerotic lesions prone to rupture (as detected by glycophorin A) relative to lesions with early necrotic cores or plaques with PIT.1 Importantly, the degree of reactive glycophorin A staining and the level of iron deposits in the plaque corresponded to the size of the necrotic core, and changes in these variables paralleled an increase in macrophage density, suggesting that hemorrhage itself serves as an inflammatory stimulus (Table 2).1 By contributing to the deposition of free cholesterol, macrophage infiltration, and enlargement of the necrotic core, the accumulation of erythrocyte membranes within an atherosclerotic plaque may represent a potent atherogenic stimulus. These factors may increase the risk of plaque destabilization.
|
|
Erythrocyte Membrane-Derived Free Cholesterol and Plaque Progression |
|---|
As proof of concept, we developed an animal model of simulated intraplaque hemorrhage to assess the role of erythrocytes in lesion progression.1 The direct injection of packed erythrocytes (25 to 50 µL) into quiescent aortic atherosclerotic plaques produced excessive macrophage infiltration along with free cholesterol crystals, and iron colocalized to areas of RBCs. In contrast, control (noninjected lesions) showed the characteristics of a regressed lesion with far fewer lesional macrophages and free cholesterol. Neutral lipids identified by oil red O were also significantly greater in plaques with injected erythrocytes when compared with controls. Thus, the animal studies offer further evidence that episodic hemorrhages in plaques contribute to accumulated free cholesterol and macrophage infiltration.
The contribution of erythrocyte membrane cholesterol to necrotic core volume is predicted to be substantial because intraplaque hemorrhage is thought to occur repeatedly over years. On the basis of a liquid volume of cholesterol in a single RBC of 0.378 µm3 and a hematocrit of 
50%, an accumulation of 100 µL whole blood at a 10% cholesterol exchange efficiency would add 
0.2 mm3 to the total necrotic core volume (T.N.T., S.P.W.). This calculation represents bleed volumes of only 0.137 µL per day whole blood (0.068 µL packed RBCs) repeated over a 2-year period. Like internal bleeds, the bulk of the erythrocyte would be degraded over days, and because membrane cholesterol fraction cannot be metabolized internally, it would be available for absorption into the necrotic core. Moreover, the uptake of erythrocyte-derived cholesterol by macrophages, in turn, would inevitably give up cholesterol to the core by apoptotic cell death. Consistent with this notion, recent MRI data of carotid plaques over an 18-month period showed evidence of intraplaque hemorrhage as contributing factor to necrotic core volume and lesion bulk.33 Further, patients with intraplaque hemorrhage at baseline showed a far greater susceptibility to repeat plaque hemorrhages.33 Therefore, accumulated RBC-derived cholesterol may represent a critical transition promoting the conversion of a stable plaque to an unstable phenotype.
|
Association of Plaque Hemorrhage and Vasa Vasorum |
|---|
Pathologic examination of unstable lesions has demonstrated that intraplaque hemorrhage and plaque rupture are associated with an increased density of microvessels.34–39 The concept of how RBCs precisely leak into the necrotic core is poorly understood. Our laboratory has described diffuse perivascular staining of von Willebrand factor (vWF) within plaque vasa vasorum and evidence of erythrocyte membranes within necrotic cores (please see online supplement).1 This finding suggests that microvascular disruption or leakiness may promote lesion progression by providing erythrocyte-derived cholesterol. In addition to leaky vasa vasorum, plaque fissuring can also account for the accumulation of erythrocytes, which has also been described to occur in the coronary vasculature of patients dying from sudden coronary death. (please see online supplement).40
More than 100 cases of sudden coronary death with serial sectioning of selected plaques were examined in our laboratory to better understand the relationship of intraplaque vasa vasorum in ruptured lesions. The number of vasa vasorum was increased 2-fold in vulnerable plaques and up to 4-fold in ruptures compared with stable plaques with severe luminal narrowing (Table 1). Moreover, it was found that the invasion of intraplaque vasa vasorum from the adventitia follows a distinct pattern of arborization. The entrance into the intimal space from the adventitia occurs specifically at breakpoints in the medial layer below sites of early necrotic core formation (Figure 3). The vessels divide as they approach the core with secondary and tertiary branches surrounding its abluminal surface (Figures 1 and 3
). Microvessels close to the medial wall appear to be well formed because they are typically accompanied by surrounding SMCs. This is in contrast to intimal vessels near the lumen, which appear immature. Increased numbers of T cells are commonly found at breaks in the medial wall and base of the necrotic core compared with other regions of the plaque. It is plausible that T helper cell–driven immune responses possibly through interferon-
may inhibit SMC proliferation, contributing to medial disruption and absence of SMCs in perforating neovessels.
|
-actin ( |
The Vasa Vasorum in Atherosclerosis |
|---|
The intima of normal human coronary arteries lack vasa vasorum, whereas the adventitia and outer media possess a vascular network.41 In such vessels, endothelial cell turnover is low (labeling index <0.25%).42 Studies more than a century ago by Koester43 originally describe increased numbers of arterial microvessels in human atheroma, which have later been confirmed by several investigators.31,32,44 In more recent reports of human atherectomy specimens, endothelial cell proliferation is modest, although when neovascularization is observed, the proliferation indices as high as 43.5% may be reached.45 Barger et al demonstrated a rich network of vasa vasorum within human atherosclerotic coronary vessels.46 In an animal study, Heistead and Armstrong reported a 5-fold increase in intima/media blood flow from proliferating microvessels in monkeys fed high cholesterol for 17 months.47 Casting studies and confocal microscopy demonstrate that intimal microvessels arise more frequently from the dense network of vessels in the adventitia adjacent to a plaque rather from the arterial lumen.48 Ongoing studies in our laboratory show a correlation of angiogenesis with the extent of chronic inflammation, granulation tissue, and atherosclerotic changes (please see online supplement).
Most of the intraplaque vasa vasorum are endothelialized, but only a few have mural pericytes and SMCs. Lack of mural cells and poorly formed endothelial cell junctions probably contribute to the leakiness of the intraplaque vasa vasorum.1,36,38,49 Porous microvessels may result from release of angiogenic factors from the closely associated macrophages. It has recently been shown that a platelet-derived growth factor-ß (PDGF) gradient is involved in the recruitment of mural cells; a deficiency of PDGF receptors may impair close contact with endothelial cells forming a network of immature blood vessels.
|
Vasa Vasorum Heterogeneity Among Different Vascular Beds |
|---|
In human atherosclerosis, arterial neovascularization and inflammation were reported recently to be significantly greater in patients with signs of symptomatic than asymptomatic atherosclerotic disease in iliac, carotid, and renal arteries. Vasa vasorum correlated with intimal macrophage content; moreover they were 2- to 4-fold higher in individuals with previous cardiovascular events than those with a negative clinical history.39 Notably, this relationship was preserved in diabetic patients as well. This quantitative analysis of angiogenic and inflammatory events in the arterial vasculature provides important evidence of a more widespread involvement of neovascularization and inflammation, which likely also involves the coronary bed.
An increased heterogeneity of vasa vasorum among different vascular beds may explain the propensity for the differential expression of atherosclerotic disease at varied anatomic locations. In normal swine coronary arteries, the density of vasa vasorum measured by micro-CT was highest in coronary arteries (2.91±0.26 vessels/mm2) versus renal (1.45±0.22 vessels/mm2), carotid (0.64±0.08 vessels/mm2), and lowest in femoral arteries (0.23±0.05 vessels/mm2).54 The relationship between the adventitial vasa vasorum and the development of atherosclerosis was further supported by the observation that the internal mammary artery, a vessel with low incidence of atherosclerosis, shows significantly lower vasa vasorum density. Furthermore, the contribution of vasa vasorum to vascular disease may also be mediated by their physical fragility. Interestingly, the variability in vasa vasorum density among vascular beds was primarily accounted for by the second order vasa vasorum. These microvessels are smaller in diameter than the first-order vasa vasorum, less mature, and therefore might be more susceptible to hemorrhage.
|
Emerging Mechanisms of Plaque Angiogenesis |
|---|
Angiogenesis depends on the combined action of various cytokines and growth factors secreted by infiltrating inflammatory cells. Neovascularization commonly accompanies chronic immune and inflammatory responses characterized by prominent T-cell and macrophage infiltration (Figure 4).
|
|
T-Cell–Mediated Signaling |
|---|
Varying degrees of T lymphocytes are consistently present in areas of neoangiogenesis specifically within the deep intima and below the necrotic core and shoulder regions. These morphological observations strongly suggest that T lymphocytes likely play an important role in the development and maturation of intraplaque vasa vasorum. Activated T cells are a known source of angiogenic factors, including vascular endothelial growth factor (VEGF), and can stimulate angiogenesis in association with early lymphocyte recruitment.55 The dependency of T cells in mediating angiogenic responses was demonstrated recently in CD4 knockout mice exposed to acute hindlimb ischemia.56 Inflammation and collateral development in response to ischemia were significantly impaired in CD4–/– versus C57BL6 wild-type mice. Moreover, rescue experiments involving the infusion of spleen-derived purified CD4-positive T cells in CD4 null mice increased macrophage recruitment, resulting in blood flow recovery, limb salvage, and reduced muscle atrophy. These data highlight the importance to CD4+ cells as initiators of angiogenic responses in addition to their importance in the accumulation of macrophages, which then secrete a broad array of cytokines and growth factors, including VEGFs, which facilitate angiogenic growth.
|
Role of CD40/CD40 Ligand |
|---|
Several reports have established interactions between CD40 ligand (CD40L) and CD40 involving pluripotent functions on inflammation, including the production of cytokines and chemokines, as well as the angiogenesis factor VEGF, by endothelial cells. Activated human T cells are reported to mediate contact-dependent expression of matrix metalloproteinases (MMPs) in endothelial cells through CD40L/CD40 signaling.57 These interactions through CD40/CD40L were able to induce an angiogenic response in endothelial cells cultured in 3D fibrin matrix gels, which were sensitive to MMP inhibition. More recently, ligation of CD40 resulted in the expression of several angiogenic factors, including VEGF58 and fibroblast growth factor-2 and the receptors Flt-1 and Flt-4.59 These studies and others60–63 provide support for a proangiogenic function of CD40L–CD40 interactions.
|
Toll-Like Receptors |
|---|
The role of cytokine-driven inflammation and tissue destruction is becoming recognized as a major determinant of lesion instability.64 Production of these cytokines is initiated by signaling through Toll-like receptors (TLRs) that recognize host-derived molecules released from injured tissues and cells. TLRs activate the proinflammatory transcription factor nuclear factor
B (NF-B) and the mitogen-activated protein kinase pathway, resulting in the production of cytokines that augment local inflammation. Signaling through TLRs is facilitated by the adapter molecule protein myeloid differentiation factor 88 (MyD88) and other homologous MyD88 adapter–like proteins expressing shared homology with the intracellular signaling domains of the interleukin-1 (IL-1) receptor that are selectively involved in the various phases of NF-B activation.65 In human atherosclerotic plaques, TLR1, TLR2, and TLR4 are shown to be upregulated in the endothelium and in areas infiltrated with inflammatory cells at the mRNA and protein levels. These receptors primarily colocalized with cells expressing macrophage and endothelial cell markers, although some T cells expressed TLR2 and TLR4.66 In addition, adventitial fibroblasts and dendritic cells express functional TLR4 receptors and are able to produce a variety of cytokines after TLR4 activation.67 It has been suggested that TLRs or adapter molecules such as MyD88 highly influence atherosclerotic lesion bulk and progression. In a recent study by Michelsen et al, genetic deficiency of TLR4 or MyD88 in apolipoprotein E null mice resulted in a significant reduction of aortic atherosclerosis despite continued hypercholesterolemia.68 The reduction in atherosclerosis was associated with lower levels of circulating proinflammatory cytokines IL-12 or monocyte chemoattractant protein 1 accompanied by reduced numbers of plaque macrophages and expression of endothelial leukocyte adhesion molecules. Importantly, human studies suggest TLR4 expression is upregulated in lipid-rich human plaques when compared with fibrous plaques.69 Moreover, the capacity of innate immune system to elicit inflammation reactions in response to endotoxins is impaired in patients with TLR4 polymorphisms. These studies and others suggest that TLRs may be essential for promoting the inflammatory component of atherosclerotic disease.
Despite the effects of inflammatory cell activation on angiogenic responses, activation of TLRs may directly affect VEGF production. Activation of the cell surface G-protein–coupled adenosine receptors in murine macrophages produces, in addition to anti-inflammatory activity, an upregulation of VEGF.70,71 Although treatment of macrophages with adenosine agonists produces only a modest increase in VEGF, stimulation of the adenosine (A2AAR) receptor in the presence of TLRs results in increased VEGF secretion to a level similar to that produced under hypoxia and perhaps is the most potent inducer of VEGF expression.
The role of CD40/CD40L and TLR in the promotion of plaque angiogenesis is, at this moment, highly speculative. Experimental studies in animal models of atherosclerosis (in mice) have clearly shown a role for CD40/CD40L or TLR pathway in the development or progression of atherosclerosis; as yet, no study has shown an alteration of plaque or adventitial angiogenesis after inhibition of CD40/CD40L or inhibition of TLR signaling. Further, the presence of intraplaque vasa vasorum in mice is controversial.72,73
|
Conclusions |
|---|
Observational studies of necrotic core progression identify intraplaque hemorrhage as a critical factor in atherosclerotic plaque growth and destabilization. The rapid accumulation of erythrocyte membranes causes an acute change in plaque substrate characterized by increased free cholesterol within the core and excessive macrophage infiltration. Neoangiogenesis is closely associated with plaque progression and is likely the primary source of intraplaque hemorrhage at sites of microvessel incompetence. Focal collections of T-cell– and macrophage-derived angiogenic factors contribute to: (1) the arborization of vasa vasorum around the necrotic core; (2) the formation of immature vessels; and (3) loss of basement membrane around functional capillaries. This process initiates leakage of RBCs into the plaque and induces a cycle of inflammation and neovascularization. Understanding the mechanisms of angiogenic growth within the neointima of atherosclerotic lesions may lead to the development of new therapies designed to stabilize plaques.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grant RO1 HL61799-02.
Received February 22, 2005; accepted June 9, 2005.
|
References |
|---|
1. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003; 349: 2316–2325.
2. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310: 1137–1140.[Abstract]
3. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV, Virmani R. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001; 16: 285–292.[CrossRef][Medline] [Order article via Infotrieve]
4. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262–1275.
5. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV, Gold HK. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004; 90: 1385–1391.
6. Burke AP, Virmani R, Galis Z, Haudenschild CC, Muller JE. 34th Bethesda Conference: Task force #2—What is the pathologic basis for new atherosclerosis imaging techniques? J Am Coll Cardiol. 2003; 41: 1874–1886.
7. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994; 89: 2462–2478.
8. Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998; 97: 2307–2315.
9. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol. 1981; 103: 191–200.[Abstract]
10. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992; 267: 4143–4151.
11. Rydberg EK, Krettek A, Ullstrom C, Ekstrom K, Svensson PA, Carlsson LM, Jonsson-Rylander AC, Hansson GI, McPheat W, Wiklund O, Ohlsson BG, Hulten LM. Hypoxia increases LDL oxidation and expression of 15-lipoxygenase-2 in human macrophages. Arterioscler Thromb Vasc Biol. 2004; 24: 2040–2045.
12. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002; 8: 1211–1217.[CrossRef][Medline] [Order article via Infotrieve]
13. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta. 2000; 1529: 164–174.[Medline] [Order article via Infotrieve]
14. Dove DE, Su YR, Zhang W, Jerome WG, Swift LL, Linton MF, Fazio S. ACAT1 deficiency disrupts cholesterol efflux and alters cellular morphology in macrophages. Arterioscler Thromb Vasc Biol. 2005; 25: 128–134.
15. Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol. 1999; 19: 1891–1898.
16. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio S, Farese RV Jr. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest. 2000; 105: 711–719.[Medline] [Order article via Infotrieve]
17. Tabas I, Marathe S, Keesler GA, Beatini N, Shiratori Y. Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis. J Biol Chem. 1996; 271: 22773–22781.
18. Katz SS, Shipley GG, Small DM. Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. J Clin Invest. 1976; 58: 200–211.
19. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol. 1997; 17: 1337–1345.
20. Leon ME, Chavez C, Fyfe B, Nagorsky MJ, Garcia FU. Cholesterol granuloma of the maxillary sinus. Arch Pathol Lab Med. 2002; 126: 217–219.[Medline] [Order article via Infotrieve]
21. Virmani R, Roberts WC. Pulmonary arteries in congenital heart disease: a structure-function analysis. In: Roberts WC, ed. Adult Congenital Heart Disease. Philadelphia, Pa: F.A. Davis Company; 1987: 77–130.
22. Virmani R, Burke AP, Farb A. Non-neoplastic diseases of the pericardium. In: Atlas of Cardiovascular Pathology. Philadelphia, Pa: W.B. Saunders Company; 1996: 103–110.
23. Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta. 1985; 822: 267–287.[Medline] [Order article via Infotrieve]
24. Bloch K. Cholesterol: evolution of structure and function. In: Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins, and Membranes. Amsterdam, The Netherlands: Elsevier Science; 1991: 363–381.
25. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103: 993–999.
26. Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin Pharmacol. 2002; 58: 501–506.[CrossRef][Medline] [Order article via Infotrieve]
27. Marathe S, Kuriakose G, Williams KJ, Tabas I. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler Thromb Vasc Biol. 1999; 19: 2648–2658.
28. Guyton JR. Phospholipid hydrolytic enzymes in a ‘cesspool’ of arterial intimal lipoproteins: a mechanism for atherogenic lipid accumulation. Arterioscler Thromb Vasc Biol. 2001; 21: 884–886.
29. Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res. 1998; 39: 947–956.
30. Wartman WB. Occlusion of the coronary arteries by hemorrhage into their walls. Am Heart J. 1938; 15: 459–470.[CrossRef]
31. Winternitz MC, Thomas RM, Le Compte PM. Thrombosis. In: Thomas CC, ed. The Biology of Atherosclerosis. Springfield, Ill; 1938: 94–103.
32. Patterson JC. The reaction of the arterial wall to intramural hemorrhage. In: Symposium of Atherosclerosis. Washington, DC: National Academy of Sciences.; 1954: 65–73.
33. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, Isaac C, McDonough J, Natiello C, Small R, Ferguson MS, Hatsukami TS. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation. 2005; 111: 2768–2775.
34. Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. J Am Med Assoc. 1999; 281: 921–926.
35. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, Naylor AR, Brindle NP. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg. 1999; 30: 261–268.[CrossRef][Medline] [Order article via Infotrieve]
36. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol. 1999; 188: 189–196.[CrossRef][Medline] [Order article via Infotrieve]
37. Mofidi R, Crotty TB, McCarthy P, Sheehan SJ, Mehigan D, Keaveny TV. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg. 2001; 88: 945–950.[CrossRef][Medline] [Order article via Infotrieve]
38. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, Bult H. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2003; 23: 440–446.
39. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, Biedermann BC. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation. 2004; 110: 2843–2850.
40. Davies MJ, Thomas AC. Plaque fissuring–the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985; 53: 363–373.
41. Vancov V. Structural basis of the microcirculation in the wall of arterial vessels. Bibl Anat. 1973; 11: 383–388.[Medline] [Order article via Infotrieve]
42. Tannock IF, Hayashi S. The proliferation of capillary endothelial cells. Cancer Res. 1972; 32: 77–82.
43. Koester W. Endarteritis and arteriitis. Berl Klin Wochenschr. 1876; 13: 454–455.
44. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest. 1998; 101: 1551–1556.[Medline] [Order article via Infotrieve]
45. O’Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1994; 145: 883–894.[Abstract]
46. Barger AC, Beeuwkes R, 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984; 310: 175–177.[Medline] [Order article via Infotrieve]
47. Heistad DD, Armstrong ML. Blood flow through vasa vasorum of coronary arteries in atherosclerotic monkeys. Arteriosclerosis. 1986; 6: 326–331.
48. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993; 143: 164–172.[Abstract]
49. Virmani R, Narula J, Farb A. When neoangiogenesis ricochets. Am Heart J. 1998; 136: 937–939.[CrossRef][Medline] [Order article via Infotrieve]
50. Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong LG, Kelly DJ, Gilbert RE. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol. 2004; 164: 1263–1273.
51. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003; 162: 1083–1093.
52. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001; 153: 543–553.
53. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol. 1993; 143: 1377–1388.[Abstract]
54. Galili O, Herrmann J, Woodrum J, Sattler KJ, Lerman LO, Lerman A. Adventitial vasa vasorum heterogeneity among different vascular beds. J Vasc Surg. 2004; 40: 529–535.[CrossRef][Medline] [Order article via Infotrieve]
55. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 1876–1890.
56. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation. 2003; 108: 205–210.
57. Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol. 1999; 154: 229–238.
58. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000; 96: 3801–3808.
59. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol. 2003; 171: 1534–1541.
60. Russo S, Bussolati B, Deambrosis I, Mariano F, Camussi G. Platelet-activating factor mediates CD40-dependent angiogenesis and endothelial-smooth muscle cell interaction. J Immunol. 2003; 171: 5489–5497.
61. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003; 278: 18008–18014.
62. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004; 172: 7503–7509.
63. Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E. T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2004; 3: 35–42.[CrossRef][Medline] [Order article via Infotrieve]
64. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91: 281–291.
65. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev. 2004; 202: 250–265.[CrossRef][Medline] [Order article via Infotrieve]
66. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002; 105: 1158–1161.
67. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002; 106: 1985–1990.
68. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004; 101: 10679–10684.
69. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001; 104: 3103–3108.
70. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, Boons GJ, Leibovich SJ. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol. 2003; 163: 711–721.
71. Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002; 160: 2231–2244.
72. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000; 20: 2587–2592.
73. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003; 100: 4736–4741.
This article has been cited by other articles:
 |
|
 |
|
  M. J. Mulligan-Kehoe The vasa vasorum in diseased and nondiseased arteries Am J Physiol Heart Circ Physiol, February 1, 2010; 298(2): H295 - H305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gossl, D. Versari, H. A. Hildebrandt, T. Bajanowski, G. Sangiorgi, R. Erbel, E. L. Ritman, L. O. Lerman, and A. Lerman Segmental Heterogeneity of Vasa Vasorum Neovascularization in Human Coronary Atherosclerosis J. Am. Coll. Cardiol. Img., January 1, 2010; 3(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Finn and R. K. Jain Coronary Plaque Neovascularization and Hemorrhage: A Potential Target for Plaque Stabilization? J. Am. Coll. Cardiol. Img., January 1, 2010; 3(1): 41 - 44. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Le Dall, B. Ho-Tin-Noe, L. Louedec, O. Meilhac, C. Roncal, P. Carmeliet, S. Germain, J.-B. Michel, and X. Houard Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors Cardiovasc Res, January 1, 2010; 85(1): 184 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Giannoglou, K. C. Koskinas, D. N. Tziakas, A. G. Ziakas, A. P. Antoniadis, I. K. Tentes, and G. E. Parcharidis Total Cholesterol Content of Erythrocyte Membranes and Coronary Atherosclerosis: An Intravascular Ultrasound Pilot Study Angiology, December 1, 2009; 60(6): 676 - 682. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Kwee, G. J. J. Teule, R. J. van Oostenbrugge, W. H. Mess, M. H. Prins, R. J. van der Geest, J. W.M. ter Berg, C. L. Franke, A. G.G.C. Korten, B. J. Meems, et al. Multimodality Imaging of Carotid Artery Plaques: 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging Stroke, December 1, 2009; 40(12): 3718 - 3724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Imaging Inflammation in Atherosclerosis: Another Step Forward J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1223 - 1225. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sirol, P. R. Moreno, K.-R. Purushothaman, E. Vucic, V. Amirbekian, H.-J. Weinmann, P. Muntner, V. Fuster, and Z. A. Fayad Increased Neovascularization in Advanced Lipid-Rich Atherosclerotic Lesions Detected by Gadofluorine-M-Enhanced MRI: Implications for Plaque Vulnerability Circ Cardiovasc Imaging, September 1, 2009; 2(5): 391 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saraste, S. G. Nekolla, and M. Schwaiger Cardiovascular molecular imaging: an overview Cardiovasc Res, September 1, 2009; 83(4): 643 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yunoki, T. Naruko, R. Komatsu, S. Ehara, N. Shirai, K. Sugioka, M. Nakagawa, C. Kitabayashi, Y. Ikura, A. Itoh, et al. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes Eur. Heart J., August 1, 2009; 30(15): 1844 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Singh, A. R. Moody, D. J. Gladstone, G. Leung, R. Ravikumar, J. Zhan, and R. Maggisano Moderate Carotid Artery Stenosis: MR Imaging-depicted Intraplaque Hemorrhage Predicts Risk of Cerebrovascular Ischemic Events in Asymptomatic Men Radiology, August 1, 2009; 252(2): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, K. Sun, Y. Zhen, D. Wang, Y. Wang, J. Chen, J. Xu, F. B. Hu, and R. Hui VEGF Receptor-2 Variants Are Associated With Susceptibility to Stroke and Recurrence Stroke, August 1, 2009; 40(8): 2720 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Laitinen, A. Saraste, E. Weidl, T. Poethko, A. W. Weber, S. G. Nekolla, P. Leppanen, S. Yla-Herttuala, G. Holzlwimmer, A. Walch, et al. Evaluation of {alpha}v{beta}3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice Circ Cardiovasc Imaging, July 1, 2009; 2(4): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sluimer, F. D. Kolodgie, A. P.J.J. Bijnens, K. Maxfield, E. Pacheco, B. Kutys, H. Duimel, P. M. Frederik, V. W.M. van Hinsbergh, R. Virmani, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1517 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. I. Lobbes, R.-J. J. H. M. Miserus, S. Heeneman, V. Lima Passos, P. H. A. Mutsaers, N. Debernardi, B. Misselwitz, M. Post, M. J. A. P. Daemen, J. M. A. van Engelshoven, et al. Atherosclerosis: Contrast-enhanced MR Imaging of Vessel Wall in Rabbit Model--Comparison of Gadofosveset and Gadopentetate Dimeglumine Radiology, March 1, 2009; 250(3): 682 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Boyle, H. A. Harrington, E. Piper, K. Elderfield, J. Stark, R. C. Landis, and D. O. Haskard Coronary Intraplaque Hemorrhage Evokes a Novel Atheroprotective Macrophage Phenotype Am. J. Pathol., March 1, 2009; 174(3): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Magnoni, S. Coli, M. M. Marrocco-Trischitta, G. Melisurgo, D. De Dominicis, D. Cianflone, R. Chiesa, S. B. Feinstein, and A. Maseri Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries Eur J Echocardiogr, March 1, 2009; 10(2): 260 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Drinane, J. Mollmark, L. Zagorchev, K. Moodie, B. Sun, A. Hall, S. Shipman, P. Morganelli, M. Simons, and M. J. Mulligan-Kehoe The Antiangiogenic Activity of rPAI-123 Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque Circ. Res., February 13, 2009; 104(3): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Falk, T. Thim, and I. B. Kristensen Atherosclerotic plaque, adventitia, perivascular fat, and carotid imaging. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 183 - 186. [Full Text] [PDF]
|
|
|
|
|
|
Ph. G. Steg, K. A.A. Fox, K. A. Eagle, M. Furman, F. Van de Werf, G. Montalescot, S. G. Goodman, A. Avezum, W. Huang, J. M. Gore, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events Eur. Heart J., February 1, 2009; 30(3): 321 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Tziakas, G. K. Chalikias, I. K. Tentes, D. Stakos, S. V. Chatzikyriakou, K. Mitrousi, A. X. Kortsaris, J. C. Kaski, and H. Boudoulas Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome Eur. Heart J., November 2, 2008; 29(22): 2713 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Keeley, B. Mehrad, and R. M. Strieter Chemokines as Mediators of Neovascularization Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1928 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Leroyer, P.-E. Rautou, J.-S. Silvestre, Y. Castier, G. Leseche, C. Devue, M. Duriez, R. P. Brandes, E. Lutgens, A. Tedgui, et al. CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis: A Potential Mechanism for Intraplaque Neovascularization J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1302 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bitar, A. R. Moody, G. Leung, S. Symons, S. Crisp, J. Butany, C. Rowsell, A. Kiss, A. Nelson, and R. Maggisano In Vivo 3D High-Spatial-Resolution MR Imaging of Intraplaque Hemorrhage1 Radiology, October 1, 2008; 249(1): 259 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P.G. Hoeks, K. D. Reesink, E. Hermeling, and R. S. Reneman Local Blood Pressure Rather Than Shear Stress Should Be Blamed for Plaque Rupture J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1107 - 1108. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sluimer, A.-P. J. Bijnens, and M. J. Daemen Reply J. Am. Coll. Cardiol., September 9, 2008; 52(11): 968 - 969. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Winter, S. D. Caruthers, H. Zhang, T. A. Williams, S. A. Wickline, and G. M. Lanza Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 624 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Arbustini and F. I. Gambarin Theranostic strategy against plaque angiogenesis. J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 635 - 637. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Biasucci, M. Leo, and G. L. De Maria Local and Systemic Mechanisms of Plaque Rupture Angiology, August 1, 2008; 59(2_suppl): 73S - 76S. [Abstract] [PDF]
|
|
|
|
|
|
H. R. Underhill, V. L. Yarnykh, T. S. Hatsukami, J. Wang, N. Balu, C. E. Hayes, M. Oikawa, W. Yu, D. Xu, B. Chu, et al. Carotid Plaque Morphology and Composition: Initial Comparison between 1.5- and 3.0-T Magnetic Field Strengths Radiology, June 23, 2008; (2008) 2482071114. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Clouse, A. Sabir, C.-S. Yam, N. Yoshimura, S. Lin, F. Welty, P. Martinez-Clark, and V. Raptopoulos Measuring Noncalcified Coronary Atherosclerotic Plaque Using Voxel Analysis with MDCT Angiography: A Pilot Clinical Study Am. J. Roentgenol., June 1, 2008; 190(6): 1553 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sluimer, J.-M. Gasc, J. L. van Wanroij, N. Kisters, M. Groeneweg, M. D. Sollewijn Gelpke, J. P. Cleutjens, L. H. van den Akker, P. Corvol, B. G. Wouters, et al. Hypoxia, Hypoxia-Inducible Transcription Factor, and Macrophages in Human Atherosclerotic Plaques Are Correlated With Intraplaque Angiogenesis J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1258 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Johansson, F. Kramer, S. Barnhart, J. E. Kanter, T. Vaisar, R. D. Merrill, L. Geng, K. Oka, L. Chan, A. Chait, et al. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice PNAS, February 12, 2008; 105(6): 2082 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Leclercq, X. Houard, M. Philippe, V. Ollivier, U. Sebbag, O. Meilhac, and J.-B. Michel Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment J. Leukoc. Biol., December 1, 2007; 82(6): 1420 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Altaf, S. T. MacSweeney, J. Gladman, and D. P Auer Response to Letters by Hsieh and Chen, and by Tang et al Stroke, December 1, 2007; 38(12): e160 - e161. [Full Text] [PDF]
|
|
|
|
 |
|
 S Goode, N Altaf, R A Dineen, S Krishnan, and D Auer Intraplaque haemorrhage mimicking carotid pseudoaneurysm on magnetic resonance angiography Br. J. Radiol., November 1, 2007; 80(959): e271 - e274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gossl, L. O. Lerman, and A. Lerman Frontiers in Nephrology: Early Atherosclerosis A View Beyond the Lumen J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2836 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Chade, J. D. Krier, O. Galili, A. Lerman, and L. O. Lerman Role of Renal Cortical Neovascularization in Experimental Hypercholesterolemia Hypertension, October 1, 2007; 50(4): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Wang, D. L. Bhatt, K. A.A. Fox, S. R. Steinhubl, D. M. Brennan, W. Hacke, K.-H. Mak, T. A. Pearson, W. E. Boden, P. G. Steg, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial Eur. Heart J., September 2, 2007; 28(18): 2200 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Zhu, M. D. Bentley, A. R. Chade, E. L. Ritman, A. Lerman, and L. O. Lerman Early changes in coronary artery wall structure detected by microcomputed tomography in experimental hypercholesterolemia Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1997 - H2003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ohayon, O. Dubreuil, P. Tracqui, S. Le Floc'h, G. Rioufol, L. Chalabreysse, F. Thivolet, R. I. Pettigrew, and G. Finet Influence of residual stress/strain on the biomechanical stability of vulnerable coronary plaques: potential impact for evaluating the risk of plaque rupture Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1987 - H1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Ritman and A. Lerman The dynamic vasa vasorum Cardiovasc Res, September 1, 2007; 75(4): 649 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C.M. Siow and A. T. Churchman Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in Cardiovasc Res, September 1, 2007; 75(4): 659 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Caplice, S. Wang, M. Tracz, A. J. Croatt, J. P. Grande, Z. S. Katusic, and K. A. Nath Neoangiogenesis and the presence of progenitor cells in the venous limb of an arteriovenous fistula in the rat Am J Physiol Renal Physiol, August 1, 2007; 293(2): F470 - F475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Kanwar Functional duality of progenitor cells influxing into arteriovenous fistula during its neoangiogenesis Am J Physiol Renal Physiol, August 1, 2007; 293(2): F468 - F469. [Full Text] [PDF]
|
|
|
|
|
|
E. Groyer, A. Nicoletti, H. Ait-Oufella, J. Khallou-Laschet, A. Varthaman, A.-T. Gaston, O. Thaunat, S. V. Kaveri, R. Blatny, H. Stockinger, et al. Atheroprotective Effect of CD31 Receptor Globulin Through Enrichment of Circulating Regulatory T-Cells J. Am. Coll. Cardiol., July 24, 2007; 50(4): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Levy, K. R. Purushothaman, N. S. Levy, M. Purushothaman, M. Strauss, R. Asleh, S. Marsh, O. Cohen, S. K. Moestrup, H. J. Moller, et al. Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability Circ. Res., July 6, 2007; 101(1): 106 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saam, T. S. Hatsukami, N. Takaya, B. Chu, H. Underhill, W. S. Kerwin, J. Cai, M. S. Ferguson, and C. Yuan The Vulnerable, or High-Risk, Atherosclerotic Plaque: Noninvasive MR Imaging for Characterization and Assessment Radiology, July 1, 2007; 244(1): 64 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Daghini, X.-Y. Zhu, D. Versari, M. D. Bentley, C. Napoli, A. Lerman, and L. O. Lerman Antioxidant vitamins induce angiogenesis in the normal pig kidney Am J Physiol Renal Physiol, July 1, 2007; 293(1): F371 - F381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nuotio, P. M. Isoviita, J. Saksi, P. Ijas, J. Pitkaniemi, R. Sonninen, L. Soinne, E. Saimanen, O. Salonen, P. T. Kovanen, et al. Adipophilin Expression Is Increased in Symptomatic Carotid Atherosclerosis: Correlation With Red Blood Cells and Cholesterol Crystals * Online Data Stroke, June 1, 2007; 38(6): 1791 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hinz, S. H. Phan, V. J. Thannickal, A. Galli, M.-L. Bochaton-Piallat, and G. Gabbiani The Myofibroblast: One Function, Multiple Origins Am. J. Pathol., June 1, 2007; 170(6): 1807 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann and A. Lerman Atherosclerosis in the Back Yard J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2102 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Kolodgie, J. Narula, C. Yuan, A. P. Burke, A. V. Finn, and R. Virmani Elimination of Neoangiogenesis for Plaque Stabilization: Is There a Role for Local Drug Therapy? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2093 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Petrovan, C. D. Kaplan, R. A. Reisfeld, and L. K. Curtiss DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1095 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Altaf, S. T. MacSweeney, J. Gladman, and D. P. Auer Carotid Intraplaque Hemorrhage Predicts Recurrent Symptoms in Patients With High-Grade Carotid Stenosis Stroke, May 1, 2007; 38(5): 1633 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Schwartz, Z. S. Galis, M. E. Rosenfeld, and E. Falk Plaque Rupture in Humans and Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Zhu, E. Daghini, A. R. Chade, C. Napoli, E. L. Ritman, A. Lerman, and L. O. Lerman Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1209 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gongora-Rivera, J. Labreuche, A. Jaramillo, P. G. Steg, J.-J. Hauw, and P. Amarenco Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal Stroke Stroke, April 1, 2007; 38(4): 1203 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Levy, J. E. Levy, S. Kalet-Litman, R. Miller-Lotan, N. S. Levy, R. Asaf, J. Guetta, C. Yang, K. R. Purushothaman, V. Fuster, et al. Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Morel, F. Toti, B. Hugel, B. Bakouboula, L. Camoin-Jau, F. Dignat-George, and J.-M. Freyssinet Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2594 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Houard, A. Leclercq, V. Fontaine, M. Coutard, J.-L. Martin-Ventura, B. Ho-Tin-Noe, Z. Touat, O. Meilhac, and J.-B. Michel Retention and Activation of Blood-Borne Proteases in the Arterial Wall: Implications for Atherothrombosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A3 - A9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chen and J. P. Walterscheid Plaque Angiogenesis Versus Compensatory Arteriogenesis in Atherosclerosis Circ. Res., October 13, 2006; 99(8): 787 - 789. [Full Text] [PDF]
|
|
|
|
|
|
G. Caligiuri, S. V. Kaveri, and A. Nicoletti IL-20 and Atherosclerosis: Another Brick In the Wall. Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1929 - 1930. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Winter, A. M. Neubauer, S. D. Caruthers, T. D. Harris, J. D. Robertson, T. A. Williams, A. H. Schmieder, G. Hu, J. S. Allen, E. K. Lacy, et al. Endothelial {alpha}{nu}{beta}3 Integrin-Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2103 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Napoli, S. Williams-Ignarro, F. de Nigris, L. O. Lerman, F. P. D'Armiento, E. Crimi, R. E. Byrns, A. Casamassimi, A. Lanza, F. Gombos, et al. Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice PNAS, July 5, 2006; 103(27): 10479 - 10484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-o Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder, and P. Libby Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo Circulation, July 4, 2006; 114(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. MacDougall, F. Kramer, P. Polinsky, S. Barnhart, B. Askari, F. Johansson, R. Varon, M. E. Rosenfeld, K. Oka, L. Chan, et al. Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice Am. J. Pathol., June 1, 2006; 168(6): 2064 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qiu, A. Gabrielsen, H. E. Agardh, M. Wan, A. Wetterholm, C.-H. Wong, U. Hedin, J. Swedenborg, G. K. Hansson, B. Samuelsson, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability PNAS, May 23, 2006; 103(21): 8161 - 8166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sata Role of Circulating Vascular Progenitors in Angiogenesis, Vascular Healing, and Pulmonary Hypertension: Lessons From Animal Models Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1008 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Falk Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C7 - C12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer, P. Libby, and R. Weissleder Molecular and Cellular Imaging of Atherosclerosis: Emerging Applications J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1328 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Byfield, S. Tikku, G. H. Rothblat, K. J. Gooch, and I. Levitan OxLDL increases endothelial stiffness, force generation, and network formation J. Lipid Res., April 1, 2006; 47(4): 715 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Langheinrich, A. Michniewicz, D. G. Sedding, G. Walker, P. E. Beighley, W. S. Rau, R. M. Bohle, and E. L. Ritman Correlation of Vasa Vasorum Neovascularization and Plaque Progression in Aortas of Apolipoprotein E-/-/Low-Density Lipoprotein-/- Double Knockout Mice Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||